Streetbeat News

Earnings

INSM

Insmed announced that its Phase 3 study of Brensocatib achieved the primary endpoint for both dosage strengths, showing a statistically significant and clinically meaningful reduction in the frequency of pulmonary exacerbations compared to placebo. The study also met several secondary endpoints with statistical significance.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:33 am

ARCT

Arcturus Therapeutics (NASDAQ: ARCT) announced positive interim Phase 1b data for its cystic fibrosis treatment, ARCT-032. The data showed an average improvement of 4% FEV1 in the first four CF patients after two administrations. The company will present these findings at the European Cystic Fibrosis Conference on June 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:33 am

LITB

LightInTheBox Holding (NYSE:LITB) reported Q1 earnings per share (EPS) of $(0.03), unchanged from the same period last year. However, sales dropped significantly by 51.84% to $71.17 million from $147.78 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:21 am

BNS

Bank of Nova Scotia (BNS) reported its Q2 2024 adjusted EPS of C$1.58, beating the estimate of C$1.56. Sales were C$8.347 billion, surpassing the estimate of C$8.256 billion.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:14 am

ARWR

Arrowhead Pharmaceuticals announced positive Phase 2b study results for its investigational drug plozasiran, showing significant reductions in triglycerides and cholesterol in patients with mixed hyperlipidemia. The data were presented at the European Atherosclerosis Society Congress and published in the New England Journal of Medicine.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:06 am

BNS

Bank of Nova Scotia reported its Q2 2024 adjusted EPS of C$1.58, beating the estimate of C$1.56. However, its sales of C$8.347 billion missed the estimate of C$8.256 billion.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:06 am

BZUN

Baozun reported its Q1 financial results with an adjusted EPADS of $(0.03), which is the same as the previous year. The company also reported sales of $274.19 million, beating the estimate of $269.61 million.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:01 am

AXSM

BOWL

DKNG

FLUT

LRMR

MOMO

MPLN

SE

SSL

Several major stocks, including Hello Group, MultiPlan Corporation, Larimar Therapeutics, Bowlero Corp, DraftKings, Axsome Therapeutics, Flutter Entertainment, Sea Limited, and Sasol Limited, experienced declines in Tuesday's pre-market trading. Hello Group's significant drop followed disappointing first-quarter results.

Portfolio Pulse from Avi Kapoor

May 28, 2024 | 9:45 am

SY

So-Young International reported a significant decline in key metrics for Q1 2024 compared to the same period last year. Average mobile MAUs dropped to 2.0 million from 3.4 million, and the number of medical service providers subscribing to its platform decreased to 1,160 from 1,419. The total number of purchasing users through reservation services was 132.8 thousand, with an aggregate transaction value of RMB367.1 million.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 9:39 am

SY

So-Young International expects Q2 2024 revenue to be between $52.6M and $55.4M, slightly below the $52.49M estimate. This represents a 2.9% to 7.8% decrease from the same period in 2023, based on current market conditions and preliminary estimates.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 9:38 am